Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta (PDE6B) (PDE6B)

Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta (PDE6B) is a critical catalytic component of the rod-specific phosphodiesterase 6 (PDE6) enzyme complex, which is central to the visual phototransduction cascade in retinal rod cells [4, 7]. In the dark, high levels of cGMP keep cyclic nucleotide-gated (CNG) ion channels open; upon light stimulation, PDE6 is activated by transducin to hydrolyze cGMP, leading to channel closure and cell hyperpolarization [3, 5, 8]. Mutations in the PDE6B gene are a major cause of inherited retinal degenerations, including autosomal recessive retinitis pigmentosa and congenital stationary night blindness, due to the accumulation of cytotoxic cGMP levels or constitutive enzyme activity [6, 12, 16]. As a therapeutic target, PDE6B is the focus of gene augmentation therapies, such as HORA-PDE6B, which aim to restore functional protein expression and preserve vision [9, 10, 15]. Additionally, PDE6B is an off-target for several PDE5 inhibitors like sildenafil, which can cause transient visual disturbances by cross-inhibiting the retinal enzyme [5, 15]. Understanding the structural and functional nuances of PDE6B is vital for developing more selective inhibitors and effective genetic treatments for blindness [5, 13].

Other names

GMP-PDE betaPDEBCSNB3CSNBAD2RP40rd1Phosphodiesterase 6B

Gene augmentation; Phosphodiesterase inhibition